Winslow Capital Management LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 79.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,875,968 shares of the company’s stock after buying an additional 1,719,538 shares during the period. Eli Lilly and comprises about 1.6% of Winslow Capital Management LLC’s investment portfolio, making the stock its 25th largest position. Winslow Capital Management LLC owned approximately 0.37% of Eli Lilly and worth $326,008,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Heritage Trust Co acquired a new stake in Eli Lilly and during the first quarter worth $135,000. Penserra Capital Management LLC increased its stake in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the last quarter. Crestwood Advisors Group LLC acquired a new stake in Eli Lilly and during the first quarter worth $179,000. Sandy Spring Bank increased its stake in Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after buying an additional 750 shares during the last quarter. Finally, Coldstream Capital Management Inc. acquired a new stake in Eli Lilly and during the first quarter worth $200,000. Institutional investors own 75.77% of the company’s stock.

Eli Lilly and Company (NYSE:LLY) traded down 1.49% during mid-day trading on Friday, hitting $80.08. 4,345,104 shares of the company’s stock were exchanged. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The stock’s 50 day moving average price is $81.40 and its 200-day moving average price is $82.00. The stock has a market cap of $84.48 billion, a PE ratio of 34.65 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the company posted $0.86 EPS. Equities analysts expect that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.60%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is presently 90.04%.

COPYRIGHT VIOLATION WARNING: “Winslow Capital Management LLC Has $326.01 Million Position in Eli Lilly and Company (LLY)” was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/winslow-capital-management-llc-has-326-01-million-position-in-eli-lilly-and-company-lly/1538394.html.

A number of research firms have recently weighed in on LLY. BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Barclays PLC lifted their price target on shares of Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, July 4th. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. Berenberg Bank reiterated a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research report on Thursday, July 27th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 price target (up from $93.00) on shares of Eli Lilly and in a research report on Thursday, July 13th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $88.07.

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the transaction, the insider now owns 124,265,804 shares in the company, valued at approximately $10,491,761,831.72. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the transaction, the vice president now owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 849,733 shares of company stock worth $70,436,087. 0.20% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.